Author(s):
Cano, Amanda ; Ettcheto, Miren ; Espina, Marta ; Auladell, Carmen ; Folch, Jaume ; Kühne, Britta A ; Barenys, Marta ; Sánchez-López, Elena ; Souto, Eliana B. ; García, Maria Luisa ; Turowski, Patric ; Camins, Antonio
Date: 2020
Persistent ID: https://hdl.handle.net/1822/74411
Origin: RepositóriUM - Universidade do Minho
Subject(s): 3-nitropropionic acide; pigallocatechin-3-gallate; Huntingtons disease; neurodegenerative diseases; PLGA-PEG; polymeric nanoparticles; 3-nitropropionic acid; epigallocatechin-3-gallate
Description
Aim: To compare free and nanoparticle (NP)-encapsulated epigallocatechin-3-gallate (EGCG) for the treatment of Huntingtons disease (HD)-like symptoms in mice. Materials \& methods: EGCG was incorporated into PEGylated poly(lactic-co-glycolic) acid NPs with ascorbic acid (AA). HD-like striatal lesions and motor deficit were induced in mice by 3-nitropropionic acid-intoxication. EGCG and EGCG/AA NPs were co-administered and behavioral motor assessments and striatal histology performed after 5 days. Results: EGCG/AA NPs were significantly more effective than free EGCG in reducing motor disturbances and depression-like behavior associated with 3-nitropropionic acid toxicity. EGCG/AA NPs treatment also mitigated neuroinflammation and prevented neuronal loss. Conclusion: NP encapsulation enhances therapeutic robustness of EGCG in this model of HD symptomatology. Together with our previous findings, this highlights the potential of EGCG/AA NPs in the symptomatic treatment of neurodegenerative diseases.
